Tags

Type your tag names separated by a space and hit enter

Blood pressure, hematologic and erythrocyte fragility changes in children suffering from sickle cell anemia following ascorbic acid supplementation.
J Trop Pediatr. 2002 12; 48(6):366-70.JT

Abstract

The effect of ascorbic acid supplementation (100 mg/day for 6 weeks) on blood pressure, packed cell volume, irreversibly sickled cells, per cent fetal hemoglobin, hemoglobin concentration, and erythrocyte osmotic fragility was assessed in children suffering from sickle cell anemia. Fifteen children whose ages ranged from 4 to 11 years (7.5 +/- 0.75 years) were studied. Ascorbic acid supplementation reduced systolic blood pressure by 10.9 +/- 3.4 mmHg (p < 0.01), diastolic blood pressure by 7.3 +/- 2.0 mmHg (p < 0.01) and mean arterial pressure by 9.4 +/- 2.6 mmHg (p < 0.01). It significantly increased packed cell volume (p < 0.001), hemoglobin concentration (p < 0.001) and per cent fetal hemoglobin (p < 0.001), but reduced per cent irreversibly sickled cells (p < 0.001). Ascorbic acid supplementation also abolished the long tail of the erythrocyte osmotic fragiligram and increased the resistance of the cells to lysis.

Links

Publisher Full Text

Authors+Show Affiliations

Jaja SI
Department of Physiology, College of Medicine, University of Lagos, Nigeria. sjaja4@yahoo.com
Ikotun AR
No affiliation info available
Gbenebitse S
No affiliation info available
Temiye EO
No affiliation info available

MeSH

Anemia, Sickle CellAscorbic AcidBlood PressureChildChild, PreschoolData Interpretation, StatisticalErythrocytes, AbnormalFemaleFetal HemoglobinHematocritHumansMaleNigeriaOsmotic Fragility

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12521281

Citation

Jaja, S I., et al. "Blood Pressure, Hematologic and Erythrocyte Fragility Changes in Children Suffering From Sickle Cell Anemia Following Ascorbic Acid Supplementation." Journal of Tropical Pediatrics, vol. 48, no. 6, 2002, pp. 366-70.
Jaja SI, Ikotun AR, Gbenebitse S, et al. Blood pressure, hematologic and erythrocyte fragility changes in children suffering from sickle cell anemia following ascorbic acid supplementation. J Trop Pediatr. 2002;48(6):366-70.
Jaja, S. I., Ikotun, A. R., Gbenebitse, S., & Temiye, E. O. (2002). Blood pressure, hematologic and erythrocyte fragility changes in children suffering from sickle cell anemia following ascorbic acid supplementation. Journal of Tropical Pediatrics, 48(6), 366-70. https://doi.org/10.1093/tropej/48.6.366
Jaja SI, et al. Blood Pressure, Hematologic and Erythrocyte Fragility Changes in Children Suffering From Sickle Cell Anemia Following Ascorbic Acid Supplementation. J Trop Pediatr. 2002;48(6):366-70. PubMed PMID: 12521281.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blood pressure, hematologic and erythrocyte fragility changes in children suffering from sickle cell anemia following ascorbic acid supplementation. AU - Jaja,S I, AU - Ikotun,A R, AU - Gbenebitse,S, AU - Temiye,E O, PY - 2003/1/11/pubmed PY - 2003/2/13/medline PY - 2003/1/11/entrez SP - 366 EP - 70 JF - Journal of tropical pediatrics JO - J Trop Pediatr VL - 48 IS - 6 N2 - The effect of ascorbic acid supplementation (100 mg/day for 6 weeks) on blood pressure, packed cell volume, irreversibly sickled cells, per cent fetal hemoglobin, hemoglobin concentration, and erythrocyte osmotic fragility was assessed in children suffering from sickle cell anemia. Fifteen children whose ages ranged from 4 to 11 years (7.5 +/- 0.75 years) were studied. Ascorbic acid supplementation reduced systolic blood pressure by 10.9 +/- 3.4 mmHg (p < 0.01), diastolic blood pressure by 7.3 +/- 2.0 mmHg (p < 0.01) and mean arterial pressure by 9.4 +/- 2.6 mmHg (p < 0.01). It significantly increased packed cell volume (p < 0.001), hemoglobin concentration (p < 0.001) and per cent fetal hemoglobin (p < 0.001), but reduced per cent irreversibly sickled cells (p < 0.001). Ascorbic acid supplementation also abolished the long tail of the erythrocyte osmotic fragiligram and increased the resistance of the cells to lysis. SN - 0142-6338 UR - https://www.unboundmedicine.com/medline/citation/12521281/full_citation L2 - https://academic.oup.com/tropej/article-lookup/doi/10.1093/tropej/48.6.366 DB - PRIME DP - Unbound Medicine ER -